BiotechTube
Home/Amplo Biotechnology/Patricio Sepulveda
PS

Patricio Sepulveda

CEO

Amplo Biotechnology

Therapeutic Areas

Neuromuscular DiseasesRare DiseasesGenetic Disorders

Amplo Biotechnology Pipeline

DrugIndicationPhase
AMP-101Dok-7 Congenital Myasthenic Syndrome (CMS)Preclinical
AMP-201ColQ Congenital Myasthenic Syndrome (CMS)Preclinical

Leadership Team at Amplo Biotechnology

AH
Al Hawkins
President
DB
Dan Bradbury
Executive Chair
CC
Claudia Canzonetta
Program Director
View full Amplo Biotechnology profile